Literature DB >> 29311245

Both Major Histocompatibility Complex Class I (MHC-I) and MHC-II Molecules Are Required, while MHC-I Appears To Play a Critical Role in Host Defense against Primary Coxiella burnetii Infection.

Laura Buttrum1, Lindsey Ledbetter1, Rama Cherla1, Yan Zhang1, William J Mitchell1, Guoquan Zhang2.   

Abstract

To understand the role of class I major histocompatibility complex (MHC-I) and class II MHC (MHC-II) antigen presentation pathways in host defense against Coxiella burnetii infection, we examined whether MHC-I or MHC-II deficiency in mice would significantly influence their susceptibility to virulent C. burnetii Nine Mile phase I (NMI) infection. The results indicate that NMI infection induced more severe disease in both MHC-I-deficient and MHC-II-deficient mice than in wild-type (WT) mice, while only MHC-I-deficient mice developed a severe persistent infection and were unable to control bacterial replication. These results suggest that both MHC-I-restricted CD8+ T cells and MHC-II-restricted CD4+ T cells contribute to host defense against primary C. burnetii infection, while MHC-I-restricted CD8+ T cells appear to play a more critical role in controlling bacterial replication. Additionally, although NMI infection induced more severe disease in TAP1-deficient mice than in their WT counterparts, TAP1 deficiency in mice did not significantly influence their ability to eliminate C. burnetii This suggests that C. burnetii antigen presentation to CD8+ T cells by the MHC-I classical pathway may depend only partially on TAP1. Furthermore, granzyme B deficiency in mice did not significantly alter their susceptibility to C. burnetii infection, but perforin-deficient mice were unable to control host inflammatory responses during primary C. burnetii infection. These results suggest that perforin, but not granzyme B, is required for C. burnetii antigen-specific cytotoxic CD8+ T cells to control primary C. burnetii infection.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CTL; Coxiella burnetii; MHC-I; MHC-II; TAP; antigen presentation; granzyme; immune response; perforin

Mesh:

Substances:

Year:  2018        PMID: 29311245      PMCID: PMC5865044          DOI: 10.1128/IAI.00602-17

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination.

Authors:  Eunju O; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Yu-Na Lee; Jae-Min Song; Young-Man Kwon; Min-Chul Kim; Daniel R Perez; Sang-Moo Kang
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

2.  MHC class II molecules are not required for survival of newly generated CD4+ T cells, but affect their long-term life span.

Authors:  S Takeda; H R Rodewald; H Arakawa; H Bluethmann; T Shimizu
Journal:  Immunity       Date:  1996-09       Impact factor: 31.745

Review 3.  Treatment of Q fever.

Authors:  D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 4.  Vascular complications of Q-fever infections.

Authors:  M C A Wegdam-Blans; T Vainas; M R van Sambeek; P W Cuypers; H T J Tjhie; A H M van Straten; J A Teijink
Journal:  Eur J Vasc Endovasc Surg       Date:  2011-05-31       Impact factor: 7.069

5.  Long-term outcome of Q fever endocarditis: a 26-year personal survey.

Authors:  Matthieu Million; Franck Thuny; Hervé Richet; Didier Raoult
Journal:  Lancet Infect Dis       Date:  2010-07-14       Impact factor: 25.071

6.  SCID mouse model for lethal Q fever.

Authors:  Masako Andoh; Takashi Naganawa; Akitoyo Hotta; Tsuyoshi Yamaguchi; Hideto Fukushi; Toshiaki Masegi; Katsuya Hirai
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  Functional characterization of class Ia- and non-class Ia-restricted Chlamydia-reactive CD8+ T cell responses in humans.

Authors:  Ana L Gervassi; Peter Probst; Walter E Stamm; Jeanne Marrazzo; Kenneth H Grabstein; Mark R Alderson
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

8.  Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB/c mice.

Authors:  Guoquan Zhang; Kasi E Russell-Lodrigue; Masako Andoh; Yan Zhang; Laura R Hendrix; James E Samuel
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

9.  Coxiella burnetii induces apoptosis during early stage infection via a caspase-independent pathway in human monocytic THP-1 cells.

Authors:  Yan Zhang; Guoquan Zhang; Laura R Hendrix; Vernon L Tesh; James E Samuel
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

10.  Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.

Authors:  T H Ermak; P J Giannasca; R Nichols; G A Myers; J Nedrud; R Weltzin; C K Lee; H Kleanthous; T P Monath
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunogenicity and Reactogenicity in Q Fever Vaccine Development.

Authors:  Alycia P Fratzke; Erin J van Schaik; James E Samuel
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

2.  Major Histocompatibility Complex Class II-Restricted, CD4+ T Cell-Dependent and -Independent Mechanisms Are Required for Vaccine-Induced Protective Immunity against Coxiella burnetii.

Authors:  Lindsey Ledbetter; Rama Cherla; Catherine Chambers; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

3.  Coxiella burnetii-Infected NK Cells Release Infectious Bacteria by Degranulation.

Authors:  Svea Matthiesen; Luca Zaeck; Kati Franzke; Rico Jahnke; Charlie Fricke; Michael Mauermeir; Stefan Finke; Anja Lührmann; Michael R Knittler
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

4.  Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine.

Authors:  Anja Scholzen; Guilhem Richard; Leonard Moise; Laurie A Baeten; Patrick M Reeves; William D Martin; Timothy A Brauns; Christine M Boyle; Susan Raju Paul; Richard Bucala; Richard A Bowen; Anja Garritsen; Anne S De Groot; Ann E Sluder; Mark C Poznansky
Journal:  Front Immunol       Date:  2019-02-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.